Shares in AB Science-Promesses SA edged slightly upward during their first day of trading on Compartment B of the NYSE Euronext Exchange in Paris Monday, closing at €12.68 (US$16.84), just above the initial public offering price of €12.65 per share. The transaction yielded total proceeds of €27.5 million, €16.5 million of which is available to the company. The rest goes to selling shareholders. (BioWorld International)
Shares in ThromboGenics NV reached an all-time during early trading Tuesday on news that its lead drug candidate, microplasmin, reached the primary endpoint in the first of two Phase III trials in the treatment of symptomatic focal vitreomacular adhesion (VMA). (BioWorld International)
